Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

<table>EGFR Exon 19 deletions. M: molecular weight markers; 1, 3, 4: WT Exon 19 EGFR; 2: delL747-P753insS Exon 19 and EGFR gene amplification; 5: delL747-P753insS Exon 19 EGFR.</table>

Journal of Oncology

fig1

Figure 1

Figure 1: Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study 

Figure 1 | Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study 